JPWO2022178367A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022178367A5
JPWO2022178367A5 JP2023551146A JP2023551146A JPWO2022178367A5 JP WO2022178367 A5 JPWO2022178367 A5 JP WO2022178367A5 JP 2023551146 A JP2023551146 A JP 2023551146A JP 2023551146 A JP2023551146 A JP 2023551146A JP WO2022178367 A5 JPWO2022178367 A5 JP WO2022178367A5
Authority
JP
Japan
Prior art keywords
domain
cell
antigen
receptor
sar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518011A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017177 external-priority patent/WO2022178367A2/en
Publication of JP2024518011A publication Critical patent/JP2024518011A/ja
Publication of JPWO2022178367A5 publication Critical patent/JPWO2022178367A5/ja
Pending legal-status Critical Current

Links

JP2023551146A 2021-02-19 2022-02-21 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 Pending JP2024518011A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163151421P 2021-02-19 2021-02-19
US63/151,421 2021-02-19
US202163245181P 2021-09-16 2021-09-16
US63/245,181 2021-09-16
PCT/US2022/017177 WO2022178367A2 (en) 2021-02-19 2022-02-21 Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Publications (2)

Publication Number Publication Date
JP2024518011A JP2024518011A (ja) 2024-04-24
JPWO2022178367A5 true JPWO2022178367A5 (enExample) 2025-04-10

Family

ID=82932320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551146A Pending JP2024518011A (ja) 2021-02-19 2022-02-21 多様な免疫細胞のための単鎖および多鎖合成抗原受容体

Country Status (8)

Country Link
US (1) US20240390496A1 (enExample)
EP (1) EP4297769A2 (enExample)
JP (1) JP2024518011A (enExample)
KR (1) KR20230153529A (enExample)
AU (1) AU2022224066A1 (enExample)
CA (1) CA3208717A1 (enExample)
IL (1) IL305175A (enExample)
WO (1) WO2022178367A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2871146T3 (es) 2017-07-14 2021-10-28 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2019279084B2 (en) * 2018-06-01 2025-04-17 Angeles Therapeutics, Inc. Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
EP4114861A4 (en) * 2020-03-02 2024-05-08 The Regents Of The University Of California CHIMERIC ANTIGEN RECEPTORS AND RELATED COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
AR130387A1 (es) * 2022-09-08 2024-12-04 Hoffmann La Roche Receptores de linfocitos t recombinantes
CN118146393A (zh) * 2022-11-07 2024-06-07 武汉波睿达生物科技有限公司 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用
WO2024102954A1 (en) * 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
IL321737A (en) * 2023-01-05 2025-08-01 Angeles Therapeutics Inc Methods and compositions for gene transformation and control of activity of synthetic and immune receptors
SE2350348A1 (en) * 2023-03-28 2024-09-29 Bjoerefeldt Andreas Microglial endocytic receptors for use in the treatment of neurodegenerative disease
EP4619421A2 (en) * 2023-05-01 2025-09-24 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Mutant interleukin 15 expressing immune cells
WO2024238962A1 (en) * 2023-05-18 2024-11-21 A2 Biotherapeutics, Inc. Immune cells with paired receptors and uses thereof
WO2025029597A1 (en) * 2023-07-28 2025-02-06 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
US20250108114A1 (en) * 2023-09-28 2025-04-03 PELL Bio-Med Technology Co., Ltd. Isolated nucleic acid molecule comprising nkp30 transmembrane domain and chimeric antigen receptor comprising the same
WO2025193475A1 (en) * 2024-03-14 2025-09-18 The Regents Of The University Of California Enhancing immune cell innate and adaptive responses
WO2025194049A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Engineered immune cells and methods of using the same
WO2025235862A1 (en) * 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131425A2 (en) * 1998-11-18 2001-09-12 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
EP2478760A1 (en) * 2005-05-10 2012-07-25 Monsanto Technology LLC Genes and uses for plant improvement
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
WO2014039961A1 (en) * 2012-09-07 2014-03-13 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2016014565A2 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
KR102751730B1 (ko) * 2015-03-27 2025-01-10 이뮤너티바이오, 인크. 암의 치료를 위한 유전적으로 변형된 nk-92 세포 및 모노클로날 항체
JP7015551B2 (ja) * 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CA3044682A1 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
IL296050B2 (en) * 2018-08-01 2024-12-01 Immunitybio Inc A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies

Similar Documents

Publication Publication Date Title
JPWO2022178367A5 (enExample)
US20240390496A1 (en) Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP2020500530A5 (enExample)
JPWO2021188599A5 (enExample)
JP2021500861A5 (enExample)
JP2025037871A5 (enExample)
US11760806B2 (en) CD-38 directed chimeric antigen receptor constructs
JP2019518424A5 (enExample)
JP2019525956A5 (enExample)
US20220389075A1 (en) Engineered t cell receptors and uses thereof
AU2021307614A1 (en) Engineered immune cell for allotransplantation
JP2017513818A5 (enExample)
KR20210126008A (ko) 세포 면역 치료의 조합
RU2018122106A (ru) Буферы для стабилизации лентивирусных препаратов
IL297514A (en) Vectors and methods for in vivo transduction
WO2020057641A1 (zh) 表达有趋化因子的细胞及用途
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
EP3728322A1 (en) Single- and multi-chain chimeric antigen receptors
WO2021030182A1 (en) Bifunctional single variable domain t cell receptors and uses thereof
JP2020512009A (ja) キメラポリペプチド及びそれらの細胞膜における局在を変更する方法
CN110511912A (zh) 免疫细胞的功能调节
JPWO2021071962A5 (enExample)
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
CN117683139A (zh) 组成型嵌合细胞因子受体及表达其的免疫细胞及应用